NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, has announced that its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo ebolavirus and other Ebola viruses in the Democratic Republic of Congo (DRC) has been registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. This registration follows local regulatory approval from ACOREP, and the company has confirmed that NV-387 has been delivered to the clinical trial site in Ituri province, with first patient dosing anticipated within one to two weeks, barring outbreak-related impediments.
The adaptive trial will begin with a single-arm safety and dose run-in before progressing to a randomized, controlled, open-label efficacy evaluation. This design allows for flexibility in response to emerging data, which is crucial in the context of an outbreak. NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. It is also being evaluated in a Phase II clinical trial for Mpox in the DRC, highlighting its potential as a versatile therapeutic agent.
The significance of this development lies in the urgent need for effective treatments against Ebola viruses, which cause severe hemorrhagic fevers with high fatality rates. The current outbreak in the DRC, caused by the Bundibugyo strain, underscores the ongoing threat. An oral antiviral like NV-387, if proven effective, could offer a more accessible and easier-to-administer treatment option compared to injectable therapies, potentially improving patient outcomes and facilitating broader use in resource-limited settings.
NanoViricides' platform technology is based on the TheraCour nanomedicine technology, which it licenses exclusively for several viruses, including Ebola and Marburg viruses. The company's lead drug candidate, NV-387, is also being developed for respiratory infections like RSV, COVID-19, and influenza, as well as other viral diseases. This broad-spectrum approach is innovative, as it targets host-side features common to many viruses, potentially reducing the likelihood of resistance.
The registration of this trial is a critical step in advancing NV-387 through clinical development. According to the company, the trial's adaptive design allows for modifications based on interim results, which could accelerate the path to regulatory approval. The company has previously received approval from ACOREP, and the delivery of the drug to the trial site indicates that logistics are in place.
However, the company cautions that drug development is lengthy and capital-intensive, and there is no assurance that NV-387 will demonstrate sufficient safety and efficacy in human trials. The Ebola trial is part of a broader strategy to address multiple viral threats, and the outcomes will inform future development efforts. For more information on NanoViricides and its pipeline, visit the company's newsroom at https://nnw.fm/NNVC.
